NF-YA promotes invasion and angiogenesis by upregulating EZH2-STAT3 signaling in human melanoma cells

Oncology Reports

Volumn 35, Issue 6, 2016, Pages 3630-3638

  Xu, Zihan ^a   Sun, Yaowen ^a   Guo, Yadong ^a   Qin, Gaoping ^a   Mu, Shengzhi ^a   Fan, Ronghui ^a   Wang, Benfeng ^a   Gao, Wenjie ^a   Wu, Hangli ^a   Wang, Guodong ^a   Zhang, Zhenxin ^a  

^a SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Angiogenesis; Enhancer of zeste homolog 2; Nuclear transcription factor Y alpha; STAT3; Vascular endothelial growth factor

Indexed keywords

NUCLEAR FACTOR Y; NUCLEAR FACTOR Y ALPHA; POLYCOMB REPRESSIVE COMPLEX 2; STAT3 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; VASCULOTROPIN; CCAAT BINDING FACTOR; EZH2 PROTEIN, HUMAN; NFYA PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; CANCER INCIDENCE; CATALYSIS; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MELANOMA; MELANOMA CELL LINE; PRIORITY JOURNAL; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PURIFICATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; HEK293 CELL LINE; METABOLISM; METHYLATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SECRETION (PROCESS); TUMOR CELL LINE; TUMOR INVASION; UMBILICAL VEIN ENDOTHELIAL CELL;

CCAAT-BINDING FACTOR; CELL LINE, TUMOR; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MELANOMA; METHYLATION; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84964912993     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4761     Document Type: Article

References (39)

1. Tas F: Metastatic behavior in melanoma: Timing, pattern, survival, and influencing factors. J Oncol 2012: 647684, 2012.
2. Geller AC, Clapp RW, Sober AJ, Gonsalves L, Mueller L, Christiansen CL, Shaikh W and Miller DR: Melanoma epidemic: An analysis of six decades of data from the Connecticut Tumor Registry. J Clin Oncol 31: 4172-4178, 2013.
3. Mehlen P and Puisieux A: Metastasis: A question of life or death. Nat Rev Cancer 6: 449-458, 2006.
4. Lamalice L, Le Boeuf F and Huot J: Endothelial cell migration during angiogenesis. Circ Res 100: 782-794, 2007.
5. Schaafhausen MK, Yang WJ, Centanin L, Wittbrodt J, Bosserhoff A, Fischer A, Schartl M and Meierjohann S: Tumor angiogenesis is caused by single melanoma cells in a manner dependent on reactive oxygen species and NF-κB. J Cell Sci 126: 3862-3872, 2013.
6. Ellis LM and Hicklin DJ : VEGF- Targeted therapy: Mechanisms of anti- Tumour activity. Nat Rev Cancer 8: 579-591, 2008.
7. Welti J, Loges S, Dimmeler S and Carmeliet P: Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 123: 3190-3200, 2013.
8. Jia X, Hong Q, Lei L, Li D, Li J, Mo M, Wang Y, Shao Z, Shen Z, Cheng J, et al: Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer. Oncotarget 6: 8648-8662, 2015.
9. Yeh JJ and Kim WY: Targeting tumor hypoxia with hypoxia- Activated prodrugs. J Clin Oncol 33: 1505-1508, 2015.
10. Cao D, Zhou H, Zhao J, Jin L, Yu W, Yan H, Hu Y and Guo T: PGC-1α integrates glucose metabolism and angiogenesis in multiple myeloma cells by regulating VEGF and GLUT-4. Oncol Rep 31: 1205-1210, 2014.
11. Zhang C, Li Y, Cornelia R, Swisher S and Kim H: Regulation of VEGF expression by HIF-1α in the femoral head cartilage following ischemia osteonecrosis. Sci Rep 2: 650, 2012.
12. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN and Hsieh CY: Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22: 1517-1527, 2003.
13. Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D'Acquisto F, Addeo R, Makuuchi M and Esumi H: Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: Control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95: 189-197, 2000.
14. Levy DE and Darnell JE Jr: Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662, 2002.
15. Zhuang S: Regulation of STAT signaling by acetylation. Cell Signal 25: 1924-1931, 2013.
16. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, et al: Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62: 6659-6666, 2002.
17. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
18. Rao RA, Dhele N, Cheemadan S, Ketkar A, Jayandharan GR, Palakodeti D and Rampalli S: Ezh2 mediated H3K27me3 activity facilitates somatic transition during human pluripotent reprogramming. Sci Rep 5: 8229, 2015.
19. Caganova M, Carrisi C, Varano G, Mainoldi F, Zanardi F, Germain PL, George L, Alberghini F, Ferrarini L, Talukder AK, et al: Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest 123: 5009-5022, 2013.
20. Lee JM, Lee JS, Kim H, Kim K, Park H, Kim JY, Lee SH, Kim IS, Kim J, Lee M, et al: EZH2 generates a methyl degron that is recognized by the DCAF1/DD B1/CUL4 E3 ubiquitin ligase complex. Mol Cell 48: 572-586, 2012.
21. Gunawan M, Venkatesan N, Loh JT, Wong JF, Berger H, Neo WH, Li LY, La Win MK, Yau YH, Guo T, et al: The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin. Nat Immunol 16: 505-516, 2015.
22. Tong Q, He S, Xie F, Mochizuki K, Liu Y, Mochizuki I, Meng L, Sun H, Zhang Y, Guo Y, et al: Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 cell responses mediating aplastic anemia in mice. J Immunol 192: 5012-5022, 2014.
23. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, et al: Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23: 839-852, 2013.
24. Domashenko AD, Wiener S and Emerson SG: NF-Ya protein delivery as a tool for hematopoietic progenitor cell expansion. Methods Mol Biol 916: 303-316, 2012.
25. Lin YC, Chen YN, Lin KF, Wang FF, Chou TY and Chen MY: Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage. Cell Death Dis 5: E987, 2014.
26. Domashenko AD, Danet-Desnoyers G, Aron A, Carroll MP and Emerson SG: TAT-mediated transduction of NF-Ya peptide induces the ex vivo proliferation and engraftment potential of human hematopoietic progenitor cells. Blood 116: 2676-2683, 2010.
27. Jin S, Fan F, Fan W, Zhao H, Tong T, Blanck P, Alomo I, Rajasekaran B and Zhan Q: Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD 45 following DNA damage. Oncogene 20: 2683-2690, 2001.
28. Matuoka K and Chen KY: Possible role of subunit A of nuclear factor Y (NF-YA) in normal human diploid fibroblasts during senescence. Biogerontology 1: 261-271, 2000.
29. Orgaz JL, Pandya P, Dalmeida R, Karagiannis P, Sanchez- Laorden B, Viros A, Albrengues J, Nestle FO, Ridley AJ, Gaggioli C, et al: Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nat Commun 5: 4255, 2014.
30. Eustace AJ, Crown J, Clynes M and O'Donovan N: Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med 6: 53, 2008.
31. Herraiz C, Calvo F, Pandya P, Cantelli G, Rodriguez-Hernandez I, Orgaz JL, Kang N, Chu T, Sahai E and Sanz-Moreno V: Reactivation of p53 by a cytoskeletal sensor to control the balance between DNA damage and tumor dissemination. J Natl Cancer Inst 108: pii: djv289, 2015.
32. Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W and Giraud AS: Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS One 9: E95993, 2014.
33. Zhou X, Ren Y, Liu A, Han L, Zhang K, Li S, Li P, Li P, Kang C, Wang X, et al: STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. Oncol Rep 31: 2173-2180, 2014.
34. Garipov A, Li H, Bitler BG, Thapa RJ, Balachandran S and Zhang R: NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells. Mol Cancer Res 11: 360-369, 2013.
35. Nishida N, Yano H, Nishida T, Kamura T and Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag 2: 213-219, 2006.
36. Xue Y, Lim S, Yang Y, Wang Z, Jensen LD, Hedlund EM, Andersson P, Sasahara M, Larsson O, Galter D, et al: PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 18: 100-110, 2011.
37. Mahabeleshwar GH and Byzova TV: Angiogenesis in melanoma. Semin Oncol 34: 555-565, 2007.
38. Shibuya M: Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- And pro- Angiogenic therapies. Genes Cancer 2: 1097-1105, 2011.
39. Detmar M: Tumor angiogenesis. J Investig Dermatol Symp Proc 5: 20-23, 2000.